Have you been paying attention to shares of Merit Medical (MMSI)? Shares have been on the move with the stock up 12.7% over the past month. The stock hit a new 52-week high of $109.04 in the previous session. Merit Medical has gained 12.7% since the start of the year compared to the -0.6% move for the Zacks Medical sector and the 8.6% return for the Zacks Medical - Dental Supplies industry.
The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on October 30, 2024, Merit Medical reported EPS of $0.86 versus consensus estimate of $0.8.
For the current fiscal year, Merit Medical is expected to post earnings of $3.73 per share on $1.35 billion in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $4.14 per share on $1.47 billion in revenues. This represents a year-over-year change of 10.86% and 8.6%, respectively.
Merit Medical may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Merit Medical has a Value Score of C. The stock's Growth and Momentum Scores are B and D, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 29.3X current fiscal year EPS estimates, which is a premium to the peer industry average of 18.4X. On a trailing cash flow basis, the stock currently trades at 22.6X versus its peer group's average of 17.6X. Additionally, the stock has a PEG ratio of 2.44. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Merit Medical currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Merit Medical fits the bill. Thus, it seems as though Merit Medical shares could still be poised for more gains ahead.
Shares of MMSI have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Cardinal Health, Inc. (CAH). CAH has a Zacks Rank of # 2 (Buy) and a Value Score of A, a Growth Score of C, and a Momentum Score of A.
Earnings were strong last quarter. Cardinal Health, Inc. beat our consensus estimate by 14.63%, and for the current fiscal year, CAH is expected to post earnings of $7.84 per share on revenue of $220.88 billion.
Shares of Cardinal Health, Inc. have gained 8% over the past month, and currently trade at a forward P/E of 16.3X and a P/CF of 12.12X.
The Medical - Dental Supplies industry may rank in the bottom 54% of all the industries we have in our universe, but there still looks like there are some nice tailwinds for MMSI and CAH, even beyond their own solid fundamental situation.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。